The Kansas Bioscience Authority will commit $50 million to venture capital for Kansas-based bioscience companies, the agency said today.
"Capital is the lifeblood of bioscience companies," KBA CEO Tom Thornton said in a news release.
He said those companies are suffering "for a lack of early stage capital."
The money will be invested in eight private venture capital funds "with a substantial presence in the state" and will be required to raise an additional $25 million in order to distribute the KBA funds.
Premium content for only $0.99
For the most comprehensive local coverage, subscribe today.
Read more on this story in Friday's Eagle and at Kansas.com.